Matthijs van Haren
Chief Scientific Officer Cantoni Therapeutics
Seminars
Wednesday 1st October 2025
Targeting the NNMT-Driven Epigenetic Metabolome for Transformative Metabolic Efficacy
4:00 pm
- Evaluating the inhibition of Nicotinamide N-methyltransferase (NNMT) to regulate the epigenetic metabolome and target the underlying dysfunctional biology of obesity
- Overcoming the limitations of substrate-dependent inhibition with a bisubstrate approach to ensure independent binding, ensuring potent and predictable target engagement
- Unlocking durable weight loss and metabolic health through NNMT inhibition to drive significant reductions in adiposity to improve insulin sensitivity and normalise blood glucose level
